News

SAB Biotherapeutics Announces Progress on U.S. FDA’s Phased Review of Company’s Groundbreaking DiversitAb™ Platform

-  FDA has approved five of seven sections in a rolling submission required for a New Animal Drug Application (NADA)…

2 years ago

HealthEquity Honored with 2023 Healthy Worksite Award by Utah Worksite Wellness Council

HealthEquity commitments to emotional, social and financial wellness are noted in yearly awardDRAPER, Utah, May 09, 2023 (GLOBE NEWSWIRE) --…

2 years ago

HeartSciences Announces Completion of Patient Enrollment for FDA Pivotal Study of MyoVista wavECG

Southlake, Texas, May 09, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the…

2 years ago

Catalyst Pharmaceuticals Advances sNDA Submission Plans To Increase Indicated Maximum Dose For FIRDAPSE® From 80 mg Per Day To 100 mg Per Day

Concluded Positive FDA Type-C Meeting in Early May 2023 Company On Track to Submit an sNDA Early in the Third…

2 years ago

Vaxxinity Reports First Quarter 2023 Financial Results and Provides Corporate Update

Vaxxinity corporate headquarters in Cape Canaveral, Fla. Vaxxinity corporate headquarters in Cape Canaveral, Fla. (Photo: Vaxxinity)CAPE CANAVERAL, Fla., May 09,…

2 years ago

Phathom Pharmaceuticals Presents New Data at Digestive Disease Week® (DDW) 2023

Higher H. pylori eradication rates demonstrated with vonoprazan-based regimens vs. lansoprazole triple therapy, regardless of different baseline demographics and clinical…

2 years ago

ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023

LEIDEN, Netherlands & CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated…

2 years ago

Madrigal Pharmaceuticals Provides Corporate Updates and Reports First Quarter 2023 Financial Results

Resmetirom new drug application (NDA) filing on track for Q2 2023Resmetirom has received Breakthrough Therapy designation from FDA Multiple resmetirom…

2 years ago

ORYZON to Give Updates on Corporate Progress in May-June

BioEquity Europe 2023Foro Medcap BME 2023 VI Ibero-American Congress CEAPI 2023BIO International Conference 2023Jefferies Healthcare Conference 2023MidCap Paris 2023MADRID and…

2 years ago

FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals’ Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma

Decision Follows Review of Comprehensive Safety Data Package Submitted by the Company Salarius Plans to Meet with FDA to Discuss…

2 years ago